Organisation paid for research Program year 2022 Source: CMS Open Payments

Best Clinical Trials, LLC

Neither a doctor nor a teaching hospital

Research payments

$518,423

38 payments

Through program year 2022, Best Clinical Trials, LLC is reported as receiving $518,423 in research payments, across 38 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $46,066 16
2021 Research $63,183 14
2020 Research $38,254 4
2019 Research $370,920 4

Breakdown

Who paid Research payments · program years 2019–2022
  1. Romark Laboratories, LC $362,108 2 payments
  2. Anika Therapeutics, Inc. $116,913 31 payments
  3. OptiNose US, Inc. $21,590 3 payments
  4. AstraZeneca Pharmaceuticals LP $17,812 2 payments
Studies the money was for Research payments · program years 2019–2022
  1. Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $275,319 1 payment
  2. A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee $105,951 29 payments
  3. A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza $86,789 1 payment
  4. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $17,812 2 payments
  5. A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. $15,590 2 payments
  6. A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee $8,712 1 payment
  7. A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. $6,000 1 payment
  8. A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee $2,250 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record